Rakuten Securities Inc. Cuts Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Rakuten Securities Inc. trimmed its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 41.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 175 shares of the medical equipment provider’s stock after selling 122 shares during the quarter. Rakuten Securities Inc.’s holdings in Intuitive Surgical were worth $86,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Ridgewood Investments LLC purchased a new position in shares of Intuitive Surgical during the 2nd quarter worth approximately $26,000. Godsey & Gibb Inc. raised its position in Intuitive Surgical by 140.0% in the third quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock worth $29,000 after acquiring an additional 35 shares in the last quarter. Creekmur Asset Management LLC lifted its holdings in Intuitive Surgical by 200.0% in the first quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 42 shares during the period. LGT Financial Advisors LLC boosted its position in shares of Intuitive Surgical by 415.4% during the 2nd quarter. LGT Financial Advisors LLC now owns 67 shares of the medical equipment provider’s stock worth $30,000 after purchasing an additional 54 shares in the last quarter. Finally, Delos Wealth Advisors LLC grew its stake in shares of Intuitive Surgical by 380.0% during the 1st quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 57 shares during the period. 83.64% of the stock is owned by hedge funds and other institutional investors.

Intuitive Surgical Trading Up 0.2 %

NASDAQ ISRG opened at $537.07 on Wednesday. The business’s 50-day moving average price is $494.78 and its 200 day moving average price is $453.94. Intuitive Surgical, Inc. has a twelve month low of $281.12 and a twelve month high of $542.59. The company has a market capitalization of $191.29 billion, a PE ratio of 86.35, a price-to-earnings-growth ratio of 5.27 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings data on Thursday, October 17th. The medical equipment provider reported $1.56 EPS for the quarter, beating analysts’ consensus estimates of $1.24 by $0.32. Intuitive Surgical had a net margin of 28.51% and a return on equity of 13.41%. The company had revenue of $2.04 billion during the quarter, compared to the consensus estimate of $2.01 billion. Equities analysts predict that Intuitive Surgical, Inc. will post 5.45 EPS for the current year.

Insiders Place Their Bets

In other news, insider Jamie Samath sold 269 shares of the business’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $539.89, for a total transaction of $145,230.41. Following the completion of the sale, the insider now directly owns 8,757 shares of the company’s stock, valued at $4,727,816.73. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, insider Jamie Samath sold 269 shares of the business’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $539.89, for a total transaction of $145,230.41. Following the completion of the sale, the insider now owns 8,757 shares in the company, valued at approximately $4,727,816.73. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Henry L. Charlton sold 40,243 shares of the firm’s stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the completion of the transaction, the senior vice president now owns 3,001 shares in the company, valued at $1,461,006.84. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 91,178 shares of company stock valued at $45,897,071 over the last quarter. Company insiders own 0.80% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently commented on ISRG shares. Mizuho boosted their price objective on shares of Intuitive Surgical from $440.00 to $500.00 in a report on Thursday, October 17th. Wells Fargo & Company boosted their price target on Intuitive Surgical from $466.00 to $549.00 and gave the stock an “overweight” rating in a research note on Friday, October 18th. Leerink Partners raised their price objective on Intuitive Surgical from $489.00 to $502.00 in a research note on Thursday, October 17th. Piper Sandler reiterated an “overweight” rating and set a $538.00 target price (up from $495.00) on shares of Intuitive Surgical in a research report on Friday, October 18th. Finally, Royal Bank of Canada raised their price target on Intuitive Surgical from $525.00 to $555.00 and gave the company an “outperform” rating in a research report on Friday, October 18th. One analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have issued a buy rating to the company’s stock. According to data from MarketBeat, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and a consensus price target of $513.74.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.